Melanotan II vs P21 (Cerebrolysin Analog)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

Melanotan IIP21 (Cerebrolysin Analog)
CategoryPeptidesPeptides
Standard DoseResearch indicates 250-500 mcg daily via subcutaneous injection during loading, reducing to 250 mcg 2-3 times weekly for maintenance.Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
TimingAdminister 4-6 hours before UV exposure for optimal tanning synergy. Can be taken at any time of day.Morning dosing preferred for cognitive effects.
Cycle DurationLoading phase 1-2 weeks, then maintenance as long as desired. Pigmentation fades gradually upon discontinuation.4-8 week cycles with 4-week rest periods.
Evidence Levelmoderate_humananimal_plus_anecdotal
A

Melanotan II

Peptides

Mechanism

Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that non-selectively agonizes melanocortin receptors MC1, MC3, MC4, and MC5. MC1R activation stimulates eumelanin synthesis through tyrosinase upregulation, producing tanning. MC3R activation in the CNS increases libido and produces erectile responses. MC4R activation suppresses appetite. The cyclic structure provides enhanced in vivo stability (half-life 1-2 hours) and increased blood-brain barrier permeability compared to linear alpha-MSH.

Standard Dosing

Research indicates 250-500 mcg daily via subcutaneous injection during loading, reducing to 250 mcg 2-3 times weekly for maintenance.

Timing

Administer 4-6 hours before UV exposure for optimal tanning synergy. Can be taken at any time of day.

Cycle Duration

Loading phase 1-2 weeks, then maintenance as long as desired. Pigmentation fades gradually upon discontinuation.

Side Effects

  • Nausea (common, especially during loading)
  • Facial flushing
  • Spontaneous erections
  • Appetite suppression
  • Darkening of existing moles (monitor closely)
  • Fatigue
  • New nevus formation

Contraindications

  • History of melanoma or atypical moles
  • Active skin cancer
  • Pregnancy and breastfeeding
  • Addison's disease
  • Pheochromocytoma

Best Stacking Partners

PT-141

Mechanism

P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.

Standard Dosing

Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.

Timing

Morning dosing preferred for cognitive effects.

Cycle Duration

4-8 week cycles with 4-week rest periods.

Side Effects

  • Mild headache
  • Nasal irritation (intranasal)
  • Increased appetite (CNTF pathway modulation)
  • Vivid dreams

Contraindications

  • Pregnancy and breastfeeding
  • Active seizure disorders

Best Stacking Partners

SemaxSelankDihexa

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →